

Rev01
 Update: Apr,07,2025

DATASHEET

PCSK9, His, Mouse

Cat. No.: Z06298

Product Introduction

Species	Mouse
Protein Construction	<div> <div>PCSK9 (Gln35-Gln694)_x000D_</div> <div>Accession # Q80W65</div> <div>His</div> </div> <div> <div>N-term</div> <div>C-term</div> </div>
Purity	> 95% as determined by BisTris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per µg by the LAL method.
Expression System	HEK293
Theoretical Molecular Weight	the pro-form (59 kDa) and mature form (14 kDa)
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Bis-Tris PAGE result.
Formulation	Lyophilized from 0.22µm filtered solution in 20mM Tris, 150mM NaCL, 200mM L-Aginine (pH 8.2).
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background

Target Background : Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

Synonyms : PC9; PCSK9; FH3; HCHOLA3; LDLQC1; NARC-1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China